SUMMARY
INTRODUCTION
Currently recommended primary therapies for Helicobacter pylori yield eradication rates between 75% and 85%. 1 Because these therapies are far from perfect, testing to establish successful cure is recommended in a number of circumstances including uncomplicated and complicated peptic ulcer disease, low-grade gastric mucosa associated lymphoid tissue lymphomas, dyspeptic patients who remain symptomatic following H. pylori therapy, and in those who have not completed a full course of therapy. 2 Non-invasive tests such as the urea breath test (UBT) 3 and stool antigen tests [4] [5] [6] [7] have been recommended as the preferred methods to establish H. pylori cure. Drawbacks of the UBT include the need for training in the collection, handling, transport, and storage of exhaled breath samples and the need for patient cooperation. The stool antigen test is easy to perform and can be used in children, 8, 9 however, variable sensitivity and specificity have been reported in the post-treatment setting. 6, 10, 11 Cross reactivity with antigens of other Helicobacter sp. 11 , the effect of altered intestinal transit time, high fibre diets, and interactions with medications may potentially affect the results of this test. 12 The Ez-HBT Helicobacter blood test (Ez-HBT), a test performed using serum 13 C-bicarbonate determination in whole blood, 13 has been shown to compare favourably with the 13 C-UBT and endoscopic rapid urease testing in the diagnosis of active H. pylori infection with a specificity of 96% and a sensitivity of 89-92%. 14, 15 Since these published reports, the Food and Drug Administration (FDA) has approved the Ez-HBT with a modification to include an indeterminate category. In this study, we examined the performance characteristics of the FDA-approved Ez-HBT to accurately establish success or failure of therapy in H. pylori-infected adults using the 13 C-UBT as the reference method.
MATERIALS AND METHODS

Study patients
Adult subjects with treatment-naïve, active H. pylori infection determined by either histology, rapid urease testing, or 13 C-UBT, were eligible for this multi-centre out-patient study. Patients underwent H. pylori testing for either the evaluation of dyspeptic symptoms or upon finding peptic ulcer disease or gastritis on endoscopy. Exclusion criteria included use of bismuth or antibiotics within 30 days, proton pump inhibitor use within 14 days, renal or hepatic impairment, pathological hypersecretory syndromes, and inability to provide informed consent. Enrolled patients were offered eradication therapy with two standard regimens: lansoprazole, tetracycline, pepto-bismol, and metronidazole or clarithromycin, amoxicillin, and lansoprazole. Patients underwent a 13 C-UBT and Ez-HBT 4-6 weeks after completion of therapy. Those with a negative 13 C-UBT underwent a second set of urea breath and blood tests 4-6 weeks later. Two successive negative 13 C-UBT results indicated successful treatment. Patients with a positive initial UBT were considered treatment failures and were treated with the alternative regimen after which they underwent two sets of urea breath and blood tests at 4 to 6-week intervals as described above. Patients with positive 13 C-UBT after retreatment were considered retreatment failures and were further treated at the discretion of their physicians.
Study procedures
After a 4-h fasting period, 13 C-UBT and Ez-HBT were performed according to the manufacturer's instructions by trained personnel at participating sites. Each study subject underwent baseline breath sample collection for the 13 C-UBT. According to current recommendations, basal blood samples were not collected for the Ez-HBT. Five minutes after drinking an 8 ounce can of Ensure (Abbot Laboratories, Abbot Park, IL, USA) to delay gastric emptying, study subjects ingested 125 mg of 13 C-urea (dissolved in 75 mL of sterile water). Thirty minutes after ingestion of the 13 C-urea, a 3-mL blood sample was obtained by standard venipuncture for the Ez-HBT and a breath sample was collected for the 13 C-UBT. 13 C-UBT and Ez-HBT samples were processed using gas isotope ratio mass spectrometry at a centralized location (Metabolic Solutions, Nashua, NH, USA 
Statistical analysis
We estimated, assuming an 80% eradication rate and that the UBT was 100% accurate in classifying cases, that at least 120 tests were required in the study to show that the urea blood test was greater than or equal to 90% accurate in detecting eradication, with an a risk of 0.05 and 80% power. Performance characteristics were calculated for the Ez-HBT using the 13 C-UBT as the gold standard in detecting H. pylori eradication. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the Ez-HBT were determined. Only paired 13 C-UBT and Ez-HBT data were analyzed. Data sets with indeterminate Ez-HBT results were excluded from the initial analysis. This study was approved by the institutional review board at each participating site and all enrolled patients gave informed consent.
RESULTS
Seventy-four patients with active H. pylori infection (established by either histology, rapid urease testing or 13 C-UBT) were enrolled in the study. Seventy patients received H. pylori eradication therapy and underwent subsequent 13 C-UBT and Ez-HBT testing; data on these 70 patients is presented here. Active H. pylori infection was established by two diagnostic tests in 42 (60%) patients and by one diagnostic test in the remaining 28 (40%) patients (Table 1) . Patient demographics are shown in Table 1 . Success of eradication therapy was documented with the Ez-HBT using the 13 C-UBT for comparison as the gold standard. Five patients (7%) failed the first treatment regimen and three were retreated successfully giving an overall cure rate of 97% ( Figure 1) . After H. pylori eradication therapy, 133 sets of urea breath and blood tests were generated (Figure 2 ). Fiftyeight subjects received two sets of paired urea breath and blood tests, 10 subjects received only pair of one urea breath and blood tests, one subject received three paired sets of tests, and one subject received four paired sets of tests. Four Ez-HBT tests had indeterminate results and there were three tests with no results (two UBTs had no breath gas, and one subject could not have blood drawn). These seven pairs of Ez-HBT and 13 (Table 4 ); in particular, the positive predictive value increased from 56% to 86%. Successful eradication † n = 3
Unsuccessful eradication † n = 2
Unsuccessful eradication † n = 5
H. pylori re-treatment * Determined by histology, rapid urease testing, or 13 C-UBT † Determined by 13 C-UBT testing Figure 1 . Schema of Helicobacter pylori eradication therapy.
DISCUSSION
We have previously shown the utility of the Ez-HBT for the initial diagnosis of H. pylori infection. 14, 15 In this multi-centre study, we report similar sensitivity, specificity, negative predictive value and accuracy of the Ez-HBT compared with the 13 C-UBT in confirming the eradication of H. pylori infection after treatment. Advantages of the Ez-HBT are that it is easy to collect, store, and transport blood samples, and the test may be easier to use in uncooperative patients. However, like the 13 C-UBT, the Ez-HBT also requires the use of a mass spectrophotometer. Furthermore, like the 13 C-UBT and the stool antigen test, antibiotics and proton pump inhibitors may interfere with the accuracy of the Ez-HBT. 4 The usefulness of the serum 13 a specificity of 98% and a sensitivity of 86% in the posttreatment setting. These studies of the Ez-HBT were conducted before the FDA approval of the Ez-HBT and the introduction of the indeterminate result category, which has altered the interpretation of test results. The main limitation of our study is the small sample size, in particular the small number of patients with persistent H. pylori infection following therapy. Furthermore, 
Valid sets of HP tests for analysis: 126
* HP test set = 13 C-UBT and Ez-HBT [25] [26] [27] they stress the need for avoiding cane and corn products prior to testing. 25 In the pre-treatment setting where the H. pylori density is high, it is unlikely that dietary modifications will affect test results. However, in the post-treatment setting where the H. pylori density is much lower, it is important to minimize factors that may impair test accuracy. In fact, initial descriptions of the serum 13 C-bicarbonate test compared basal with post-urea dose blood samples. 13, 24 The current FDA-approved Ez-HBT protocol, however, uses a single blood sample drawn 30 min after stable-labelled urea administration. Without the benefit of baseline breath samples, which were available to us because of the study design, we could not have determined that six of eight FP and indeterminate Ez-HBT tests were TN results. Although the performance characteristics of the Ez-HBT are acceptable in the posttreatment setting, we recommend the collection of a basal blood sample, which need only be tested in the event of an indeterminate or positive test result, will result in further improvement in test accuracy. In our study group, the use of basal samples might have prevented the unnecessary retreatment of 8.6% (6/70) of patients.
In conclusion, the Ez-HBT is a simple, non-invasive, accurate test with performance characteristics comparable with that of the 13 C-UBT in establishing H. pylori eradication after therapy. The majority of FP and indeterminate Ez-HBT test results are attributable to incomplete fasting or reflect dietary practices. We recommend further studies to investigate the utility of basal blood sample collection and the effect of nonfasting on the Ez-HBT results.
